



Published in final edited form as:

Nat Commun. ; 6: 6022. doi:10.1038/ncomms7022.

## Sorting of small infectious virus particles by flow virometry reveals distinct infectivity profiles

Raphaël Gaudin<sup>1,2,\*</sup> and Natasha S. Barteneva<sup>1,3,\*</sup>

<sup>1</sup>Program in Cellular and Molecular Medicine, Boston Children's Hospital, 200 Longwood Avenue, Boston, MA 02115, USA

<sup>2</sup>Department of Cell Biology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA

<sup>3</sup>Department of Pediatrics, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA

### Abstract

The nature and concentration of lipids and proteins at the surface of viruses are essential parameters for determining particle infectiveness. Historically, averaged bulk analysis of viral particles has been the primary method to quantitatively investigate these parameters, though this neglects heterogeneity within populations. Here we analyze the properties of Junin virus particles using a sensitive flow virometry assay and further sort virions, while conserving their infectiveness. This method allows us to characterize the relationship between infectivity, virus size, and RNA content and to compare particles secreted by Vero cells with those from physiologically relevant human primary macrophages. Our study highlights significant differences in particle infectivity according to its nature, the type of producer cells and the lipid membrane composition at the budding site. Together, our results present the flow virometry assay as a powerful and versatile tool to define virus particle profiles.

### Keywords

Junin virus; New World Arenavirus; FACS sorting; Virus sorting; Flow cytometry; Flow Virometry Assay; Primary macrophages

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Co-Corresponding authors: Raphaël Gaudin, WAB 136, 200 Longwood Avenue, Boston, MA 02115, USA, +1-617-713-8881, raphael.gaudin@childrens.harvard.edu. Natasha S. Barteneva, D-239, 210 Longwood Avenue, Boston, MA 02115, USA, +1-617-713-8930, natasha.barteneva@childrens.harvard.edu.

#### Author contributions

R.G. performed and designed experiments involving viruses. N.S.B. performed the cytometry experiments including instrument optimization and alignment, acquisition, sorting and analysis. R.G. and N.S.B. designed the experiments. R.G. wrote the manuscript and R.G. and N.S.B. commented on and corrected the manuscript.

#### Competing financial interests

The authors declare no conflict of interest.

## Introduction

The characterization of individual cells within a total population has been within reach since the introduction of flow cytometry decades ago. Additional technology improvements have given researchers the ability to sort populations of interest, cell by cell, with high accuracy while preserving cell viability and allowing further functional assays. Today, the limits of flow cytometry are repeatedly tested by the research community who aim to quantitatively analyze small biological vesicles in a similar way as has been done for cells. However, one of the main limitations of this approach is the low size sensitivity of the cytometry instrumentation, which currently remains around 300 nm at best for conventional cytometers.

Lipid bilayer membrane vesicles smaller than 300 nm are numerous both inside and outside the cell, including clathrin-coated vesicles, exosomes and viruses. A few groups have attempted to detect small vesicles by flow cytometry<sup>1-8</sup> and one group has sorted fixed bacteriophage particles and sequenced them<sup>8</sup>. Detection of small vesicles is usually performed on non-conventional custom-made cytometers and requires advanced expertise to achieve high-resolution flow cytometry. To the best of our knowledge, no one has succeeded to sort small vesicles while preserving their biological activity. As of today, while cytometry technology continues to improve, this remains a significantly challenging issue.

In our study, we use the Junin virus (JUNV) as a model system to explore small vesicle detection, sorting and functionality. JUNV is an enveloped virus and a member of the New World *Arenaviridae* family. The virus is the causative agent of the Argentine Hemorrhagic Fever, which has high mortality rates in humans (up to 30% fatality of infected patients). *Candid1*, an attenuated strain of JUNV, has been shown to confer a high rate of protection against the disease and is used as a live-attenuated vaccine in endemic regions<sup>9</sup>. This strain *Candid1* is also widely used as a laboratory model to study the biology of New World Arenaviruses. The genetic material of JUNV is composed of a Short and a Large segment of ambisense single stranded RNA. Its envelope is a Glycoprotein (GPC) responsible for the recognition of the human transferrin receptor at the surface of target cells<sup>10</sup>. Transferrin receptor expression is known to be important for efficient infection and replication of JUNV in cells, although other receptors may also play a role<sup>11-13</sup>.

It is well established that the genetic material of RNA virus populations is very heterogeneous. However, heterogeneity of the lipid and protein composition of individual virus particles remain poorly studied, and direct correlation between viral particle content and infectiveness has not been addressed, mainly due to the fact that reliable and sensitive methods have not previously been available.

Here, we develop and apply advanced flow cytometry techniques to define the infectivity profiles of viral particles according to their composition. We have optimized a very sensitive cytometry-based technique referred to as “flow virometry assay (FVA)” that enables viral particle analysis and sorting, with retention of infectivity of the sorted viruses. The instrument used contains powerful lasers, a digital focusing system and advanced optics that enable sorting on the basis of light scattering parameters in combination with fluorescent

channels. Here, FVA is used to demonstrate that virion size and the envelope glycoprotein (GPC) concentration at its surface correlates with JUNV infectivity. Moreover, by co-labeling GPC and nucleic acids of viral particles, we determine the proportions of competent particles (RNA<sup>+</sup> GPC<sup>+</sup>) in virus populations, which vary according to the fraction studied. We also compare the ability of Vero cells and human primary macrophages to secrete infectious particles and highlight that infected macrophages produce a vast number of defective particles. Finally, we show that virus particles incorporate lipid microdomain markers such as the tetraspanin CD9 and are positive for the lipid raft marker Cholera toxin B (CTB), and that disruption of these microdomains impairs viral infectivity. In conclusion, this study presents a powerful tool to analyze and sort lipid microvesicles and gives new insights into the biology of the Junin virus.

## Results

### Flow cytometry analysis of small particles

Along this study, we used a customized version of the commercial FACS Aria II Special Order (SORP) cell sorter (BD Biosciences) with a powerful 300 mW 488 nm laser and a digital focusing system (DFS) option. The instrument was equipped with a photomultiplier tube option for the forward scatter channel (FSC-PMT). The cytometer tubing was extensively cleaned and the flow sheath was highly filtered (0.45 and 0.1  $\mu\text{m}$  filters). The pressure was allowed to stabilize for at least 2 hrs before starting experiments. First, we tested the sensitivity and resolution of our instrument using various DFS parameters (Supplementary Fig. 1). The DFS is a picomotor-driven focusing device that adjusts the dimension of the beam at its intersection with the core stream to obtain a smaller focal spot resulting in a smaller observation volume, which in turn increases the scatter signal and decreases the background. Optimization of the DFS parameters shows improved capacity of our instrument to discriminate small beads according to their size (Supplementary Fig. 1). Next, we investigated whether our instrument could detect fluorescent beads of 40 and 100 nm using FSC-PMT levels and fluorescence intensity in combination (Fig. 1a–d). We could detect and discriminate fluorescent latex beads of 40 nm (coupled to APC; Fig. 1a) and 100 nm (coupled to PE; Fig. 1d) when the fluorescent channel is also used to trigger detection. However, the beads remained at the level of the background in the FSC-PMT channel. Therefore, only the combination of both fluorescence and reliable FSC-PMT channels allowed higher detection efficiency of nanosized objects, in agreement with previous observations<sup>14</sup>. The 40 nm beads coupled to APC could not be detected with the PE optical bandpass filter (575/25) and the 100 nm beads coupled to PE could not be detected with APC optical bandpass filter (Fig. 1b,c).

The 100 nm beads coupled to PE are at the limit of detection of the PMT-forward scatter alone. A main population (>95%) is found at the level of the noise, while few doublets (200 nm) and higher aggregates can also be detected (Supplementary Fig. 2a). Some of the events detected at the level of the noise have a low but significant fluorescent intensity (Supplementary Fig. 2b), suggesting that they are individual beads. Doublets can be detected by FSC-PMT alone but further confirmed when correlated by the higher fluorescence

intensity (Supplementary Fig. 2c). In conclusion, our flow cytometer allows detection of 40 and 100 nm objects by combining FSC-PMT and fluorescence intensity.

### Flow Virometry assay of the Junin virus

Arenaviruses are quite heterogeneous in size as represented in Figure 1e. The JUNV particle ranges from 40 nm to 250 nm<sup>15</sup> and is thus a good model to evaluate the ability of our system to detect small vesicles. Since cytometry refers to the measurement of cells, we call our method “Flow Virometry Assay” (FVA), to refer to the measurement of viruses<sup>7</sup>. Junin virus particles were labeled with the Alexa Fluor 647 conjugated antibody LD05 that specifically recognizes the envelope glycoprotein (GPC) of JUNV (Fig. 1e). This antibody has the advantage of being non-neutralizing (Supplementary Fig. 3a and ref.<sup>16</sup>) and can therefore be used in infectivity assays. This preparation of Alexa Fluor 647 labeled JUNV particles (JUNV-A647; see Methods) was analyzed by FVA, where at least ten thousands of events were recorded (Fig. 1g). At the same flow rate and time of analysis, running PBS alone (filtered with 0.1 µm filter) leads to very limited background signal in both FSC-PMT and fluorescent channels and very few events could be recorded (Fig. 1f). Two JUNV-A647 positive populations, which we will refer to as the low and high fractions, were distinctly discriminated by size using the FSC-PMT channel in combination with fluorescence intensity using the 640 nm laser channel (Fig. 1f). A third population, most likely corresponding to viral aggregates, was observed. Using the same parameters, comparison of polystyrene beads (Fig. 1h) and JUNV-A647 preparations (Fig. 1g) suggests that the virus particles contained in the low and high fractions are smaller than 300 nm, as expected for Arenaviruses (personal observations and ref.<sup>15</sup>). The particles present in the low fraction have a FSC-PMT at the level of the noise, but the fluorescent channel is above background (as for the 40 nm APC beads) and allows discriminating them from background (see gating in Supplementary Fig. 3b). Of note, JUNV particles are at least as bright as 40 nm APC beads (Supplementary Fig. 3c,d), therefore confirming that FVA is sensitive enough to detect very small viral particles that FSC-PMT could not resolve alone.

### Sorting of Junin virus particles

The relationship between size and scatter parameters of polystyrene beads and lipidic vesicles is not straightforward due to their different refractory indexes, and also depends on the laser alignment and optical configuration of the instrument used<sup>17</sup>. To more accurately estimate the size of virus particles in each fraction, JUNV particles analyzed by FVA were further sorted onto negatively charged carbon-coated grids maintained in position by a custom-made holder that allows overflow to be evacuated while viruses adsorb on the grid surface. After low and high fractions were sorted onto these grids, the particles were labeled with a GPC specific antibody revealed by Protein A coupled to 10 nm gold beads and negatively stained (see Methods) for transmission electron microscopy (EM) imaging. We consistently observed viral particles of 60 nm from the low fraction (Fig. 2a) and of 150 nm from the high fraction (Fig. 2b). We observed minimal side-to-side or aggregated viruses in these fractions. At this stage, precise size quantification remain difficult as some virions were damaged, likely due to particles hitting the grid at high speed and the strong chemical treatments of EM processing. To further confirm our ability to sort viral particles smaller than 300 nm, we ran sorted particles through the qViro Izon Tunable Resistive Pulse

Sensing (TRPS) methods. TRPS is a relatively recent technique used for high-throughput individual nano-particle resolution measurements as particles are driven through a size-tunable nanopore (see Methods and ref.<sup>18</sup> for details). Unsorted JUNV particles shows a wide size distribution (Fig. 2c, blue bars), while sorted particles gated on A647 fluorescent particles with FSC-PMT below 300 nm present a smaller mean size with > 95% particles indeed below 300 nm (pink bars). Of note, we could not detect particles below 90 nm in the settings used.

### Infectivity profiles of sorted particles

Taking advantage of our ability to sort viruses, we investigated whether viral particles were still infectious post-sort, and if so, what the infectious properties of the low and high fractions were. Infectiveness of 3,000 viral particles sorted from the low and high populations was evaluated by plaque assay (Fig. 3a). We reproducibly observed a two fold increase of infectivity from the high fraction compared to the low fraction (Fig. 3b). As the viruses from the high fraction could contain more genomic RNA (explaining their increased infectivity), we quantified the amount of Short and Large RNA segments by reverse transcription RT-qPCR from 20,000 sorted viruses from each fraction. At equal particle number, the high and the low fractions contain similar amounts of both Short and Large RNA segments (Fig. 3c), suggesting that the increased infectivity of the particles from the high fraction is independent of their viral RNA content. Moreover, the ratio between the Short and the Large RNA segments of JUNV was similar in both fractions as well as the unsorted JUNV stock (Fig. 3d), further indicating that sorted virus fractions share similar genomic properties.

The content of viruses released may differ according to the producer cell type. Thus, we compared JUNV particles produced by the widely used Vero cell line or by primary human macrophages derived from purified monocytes from healthy blood donor (see Methods for details). Macrophages or Vero cells infected for 1 hr with JUNV (MOI 1) were extensively washed and incubated for 36 hrs at 37°C and 5% CO<sub>2</sub>. The supernatant was processed as in Fig. 1g. Upon sorting, infectivity assays performed by plaque assays revealed that JUNV particles produced by macrophages are poorly infectious compared to Vero-produced JUNV particles, regardless of their size (Fig. 3e). Moreover, at same particle number, macrophages-derived JUNV presents a 10 fold decrease in RNA content when compared to Vero-derived JUNV (Fig. 3g), which could explain their poor infectivity efficiency.

### Correlation between Glycoprotein levels and RNA content

Since analysis of virus populations by RT-qPCR may misrepresent the actual distribution of RNA in viral particles, we took advantage of our flow virometry assay to analyze GPC expression and RNA content of the JUNV particles. Labeling of virions with either a GPC antibody (Fig. 4a) or with the high affinity nucleic acid dye YOYO-1 (Fig. 4b) highlighted that no crosstalk between channels occurs. Of note, JUNV particles contain ribosomes and we cannot exclude that the YOYO-1 staining detected by FVA represents a contribution from both ribosomal and genomic RNAs. Co-labeling of GPC and nucleic acids for analysis by FVA (Fig. 4c) allowed us to determine the amount of GPC<sup>+</sup> RNA<sup>+</sup> particles within the population, with these corresponding to the pool of likely infectious particles as they

contains two elements indispensable for virus infectivity. Interestingly, while the percentage of total RNA<sup>+</sup> particles (GPC<sup>+</sup> and GPC<sup>-</sup>) is similar in both fractions (Fig. 4d, green slices), the high fraction contained 2.5 times more RNA<sup>+</sup> GPC<sup>+</sup> particles than the low fraction (Fig. 4d, yellow slices). This finding could thus explain the increase in infectivity of the high fraction observed in Figure 3b. RT-qPCR of 20,000 particles from total RNA<sup>+</sup> or GPC<sup>+</sup> RNA<sup>+</sup> viral particles revealed that the GPC<sup>+</sup> RNA<sup>+</sup> particles are enriched in JUNV RNA (Fig. 4e,f), further indicating that these particles correspond to the pool of potentially infectious viruses.

### Role of cholesterol-enriched membranes in JUNV infectivity

Since FVA enables us to define specific virions properties, we next investigated how the cholesterol content at the plasma membrane influences JUNV budding and infectivity. Cholesterol is an important component of cellular membranes that favors protein cluster microdomains by rigidifying lipid bilayers and could therefore influence GPC and cellular components incorporation into viral particles. We first examined the viral particle surface distributions of the Tetraspanin CD9, marker of the Tetraspanin-enriched microdomains (TEM) and the Cholera toxin subunit B (CTB), which binds to GM1 gangliosides and localizes primarily to lipid rafts. Both of these plasma membrane subdomains are enriched in cholesterol<sup>19,20</sup>. FVA analysis of JUNV-A647 particles co-stained with either an anti-CD9 antibody conjugated to Phycoerythrin (CD9-PE) or a CTB recombinant protein coupled to Fluorescein isothiocyanate (CTB-FITC) revealed that JUNV particles contain high levels of CD9 and CTB (Fig. 5a,b). Single staining controls showed no crosstalk between fluorophores (Supplementary Fig. 4a,b). Immunofluorescence and confocal spinning disk microscopy of JUNV-A647 particles spread on glass and stained with CD9-PE antibody confirm that CD9 is indeed enriched at the surface of JUNV particles (Fig. 5c; Pearson correlation coefficient: 0.77 – 0.1). Moreover, staining of infected cells with GPC and CD9 antibodies also illustrate that clusters of GPC at the plasma membrane are found in CD9-enriched regions (pink arrows in Fig. 5d). These results further suggest that virions bud at specialized regions of the plasma membrane.

To investigate the role of cholesterol in JUNV budding and infectivity, we next performed FVA on viruses treated with the cholesterol depletion agent Methyl- $\beta$ -Cyclodextrin (M $\beta$ CD). The organization of both TEMs and lipid rafts are perturbed by M $\beta$ CD treatment<sup>19,20</sup>. Vero cells infected for 24 hrs with JUNV were treated for 1 hr with 10 mM M $\beta$ CD, followed by extensive washes and incubation for an additional 12 hrs. It has been previously shown that cholesterol extraction by M $\beta$ CD treatment lasts at least 12 hrs<sup>21</sup>. Harvested supernatant, containing virions produced during the 12 hrs incubation period in absence of cholesterol, was prepared as previously described in Figure 1g and analyzed by FVA. M $\beta$ CD-treated virions showed a strong reduction in CD9 staining at their surface compared to mock-treated virions (Fig. 6a,b). We then used 8,000 sorted particles from each condition to infect Vero cells. After 16 hrs, cells were harvested, fixed, permeabilized and stained with an antibody raised against the Nucleoprotein (NP) of the virus and coupled to an Alexa Fluor 647 to measure the percentage of infected cells by flow cytometry (Fig. 6c). Cells treated with M $\beta$ CD produced virions that were significantly less infectious than their

mock counterpart, suggesting that cholesterol depletion alters infectivity, potentially by interfering with GPC incorporation into viral particles.

This decrease in infectivity could also be explained by a defect in budding, as we detected half as many GPC<sup>+</sup> particles by FVA in virions coming from M $\beta$ CD-treated cells compared to virions produced by non-treated cells (Fig. 6a,b). To test this hypothesis, we used reverse transcription RT-qPCR to measure the viral RNA content of cells and supernatant in samples treated or not with M $\beta$ CD as described in Figure 6, normalized to the housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The amounts of Short and Large RNA segments in cells and supernatant were unaffected upon M $\beta$ CD treatment (Supplementary Fig. 5a,b), suggesting that cholesterol depletion does not affect JUNV budding and release. Thus, the observed decrease in GPC positive particle detection by FVA could be attributed to low GPC incorporation resulting in an inability to reach the threshold of detection of our cytometer. In conclusion, the concentration of GPC at the virion surface and potentially other cellular factors such as CD9 enrichment could be key factors to enhance viral infectivity.

## Discussion

Our study presents the first successful attempt to use high-resolution flow cytometry to analyze and sort small lipid vesicles, while preserving their biological activity, using the Junin virus as a model system. This method allows us to characterize the molecular pattern of viral particles and highlights that Junin virions are heterogeneous in morphology and nature, which influences their infectivity capacities.

We have used high-powered lasers and enhanced optics combined with a new variable digital focusing system (DFS) to improve the resolution and sensitivity of our cytometer. We have been able to detect 40 nm fluorescent beads and also to sort 50–60 nm enveloped viral particles by flow virometry using a combination of forward scatter and fluorescence intensities (Fig. 1). Previously, a few groups have been able to analyze small vesicles using flow cytometry<sup>2–8</sup>. However, to our knowledge, the study by Allen *et al*<sup>8</sup> is the only one that succeeded to sort bacteriophages (of about 200 nm in length) for further genome sequencing, although no functional biological assay post-sort could be performed.

Differentiation of single and multiple events, when analyzing cells by flow cytometry, is usually based on multiple forward scatter angles such as FSC-A, FSC-H or FSC-W parameters. In the case of small vesicles, it becomes technically challenging to prove that each sorting droplet contains a single viral particle. A previous study that attempted small particle sorting used a large 140  $\mu$ m nozzle and a sheath pressure of 5 psi<sup>3</sup> but the authors suggested that using a smaller nozzle size and higher pressure would improve the sorting of nano-sized vesicles. In agreement with this study, we found that a 70  $\mu$ m nozzle and a high flow pressure of 70 psi (482 kPa) results in a smaller drop size and therefore, statistically reduces the probability of sorting several events in a single droplet. Yet, further technological advances are required to prove in a more direct manner that each individual droplet contains a single particle.

The size of particles present in different populations has been difficult to accurately determine by direct comparison to beads, as correlation between actual bead size and instrument light scatter measurements varies according to the specific refractive index of the particles analyzed<sup>17</sup>. The most accurate way to measure the size of particles remains electron microscopy (EM). Using EM, we observed a clear difference between the low and high fractions obtained from FVA, with sizes around 60 nm and 150 nm, respectively. Moreover, we used Tunable Resistive Pulse Sensing (TSRP) to further analyze the sorted particles and confirmed that FVA allows sorting of particles smaller than 300 nm (Fig. 2c). In the future, coupling FVA to other advanced techniques of cytometry such as Pulse Shape Analysis (PulSA)<sup>22,23</sup>, could further improve resolution and may provide single molecule sensitivity as is currently achieved for techniques such as total internal reflection fluorescence (TIRF) microscopy<sup>24</sup>.

We used FVA to analyze Junin virus particles and discovered several interesting features. First, we observed that two viral populations of different sizes co-exist, though size heterogeneity is usually unexpected for small RNA viruses. Interestingly, a recent study investigating the protein composition of hundreds of single HIV virions using optical tweezers and super-resolution microscopy highlighted that HIV particles are also very heterogeneous in size and in the amount of viral envelope proteins they exhibit on their surface<sup>25</sup>. Viruses use envelope glycoproteins for the initial recognition of their cellular receptor at the surface of target cells. Such interactions are indispensable for efficient entry, infection and subsequent spreading to other cells. However, the amount of envelope proteins at the surface of a particle and the number of envelope proteins actually required to facilitate efficient cell entry is variable according to the virus family (for examples see refs.<sup>26–28</sup>). The amount of GPC incorporated by a given virus particle may be critical to establish its infectivity potential and FVA could represent a powerful tool to study the amount of receptors potentially engaged, as it has been previously investigated by light microscopy<sup>24</sup>.

Future investigations will benefit from newly developed high-resolution cytometers and microscopes to identify additional factors present at the virion surface that influence their infectivity. In our study, we hypothesized that the difference in infectivity between populations could be attributed to the virion RNA content, as JUNV possesses two segments in its genome, and therefore, small particles may encapsidate only one of the two segments. This hypothesis was ruled out by RT-qPCR experiments that demonstrated similar RNA amounts and Short/Large segment ratios between the low and high fractions (Fig. 3). Moreover, while GPC<sup>+</sup> RNA<sup>+</sup> particles were 2.5 times enriched in the high fraction compared to the low one, both fractions contained comparable percentages of total RNA<sup>+</sup> particles (Fig. 4d). These results indicate that the low fraction may contain more “naked” particles (RNA<sup>+</sup> GPC<sup>-</sup>) than the high fraction.

It is considered that the type of producer cell may affect the nature of released viruses. However, using conventional virology assays, it is intricate to correlate and control for particle size, infectivity and RNA content as a function of the cell type from which they were produced. FVA allowed us to compare the infectivity of Junin virus particles produced by physiologically relevant macrophages<sup>29,30</sup> to those produced by Vero cells. We found that JUNV particles produced by macrophages were poorly infectious compared to those



produced by Vero cells (Fig. 3e). This may be explained by the fact that Vero cells lack a functional interferon- $\alpha/\beta$  response and exhibit poor immune capacities, while macrophages are highly potent immune cells and may therefore have intrinsic mechanisms that prevent proper JUNV assembly. In the future, FVA could be further developed to determine what these mechanisms are, by investigating the role of cytokines and intracellular immune sensors during viral assembly/release.

We found that JUNV particles bud at specialized lipid membrane microdomains and disruption of these domains by cholesterol depletion decreases JUNV infectivity (Fig. 5,6). It has recently been shown that JUNV GPC associates primarily with lipid raft cholesterol-enriched membranes and that cholesterol extraction decreases GPC association with the cell membrane<sup>31</sup>. In contrast, Agnihothram *et al* reported that GPC localizes to soluble lipid microdomains distinct from conventional lipid rafts<sup>32</sup>. These two studies mainly utilized biochemical techniques to define GPC location. By FVA and confocal microscopy, we now show that JUNV particles are CD9 (tetraspanin-enriched microdomain marker) and CTB (gold standard lipid raft marker) positive. Of note, HIV induces the coalescence of lipid raft and tetraspanin-enriched microdomains<sup>33</sup> and one possibility is that JUNV operates similarly during budding, which would explain why both CD9 and CTB are found on viral particles.

Upon cholesterol depletion, we observed by RT-qPCR that the same amount of viral RNA was produced by and secreted from JUNV infected cells (Supplementary Fig. 5) but that fewer GPC positive virions were detected by FVA (Fig. 6a,b). This could be due to the cells releasing more “naked” viruses that do not have detectable levels of GPC at their surface. Depletion of cholesterol from the plasma membrane may also lead to a decreased viral particle incorporation of specific cellular lipids and proteins that are important for attachment/entry steps and thus, infectivity. Further work is required to define how cellular lipids and proteins impact virion infectiveness.

CD9 is also considered a protein marker for extracellular vesicles<sup>34,35</sup>, while CTB is an emerging marker for cellular microvesicles<sup>36–38</sup>. In our FVA experiments, a subset of virus particles negative for GPC were CTB positive, indicating that our viral preparation also contained microvesicles that were efficiently discriminated from “true” viral particles (Fig. 5b). In contrast, most CD9<sup>+</sup> events were associated with viral particles (Fig. 5a), suggesting that subpopulations of cellular lipid microvesicles co-exist in our viral preparations, and that FVA has the potential to differentiate between populations.

In conclusion, we have developed a new analytical approach to quantitatively study large numbers of functional virions in an efficient and reliable manner. The ability to resolve and sort functional subsets of nanosized lipid vesicles has broad applications in various fields. Our flow virometry assay can be applied to many virus families as well as different types of intra/extra-cellular vesicles.

## Methods

### Virus maintenance

Vero cells (ATCC) were maintained at 37°C and 5% CO<sub>2</sub> in Dulbecco's Modified Eagle's medium (DMEM) media (Life Technologies-Gibco) supplemented with 10% heat inactivated fetal bovine serum (FBS; Atlanta Biologicals), 100 IU mL<sup>-1</sup> penicillin and 100 mg mL<sup>-1</sup> streptomycin and 2 mM L-Glutamine (Life Technologies-Gibco). Within the text, Junin virus or JUNV refers to the non-pathogenic vaccine strain *Candid1* (obtained from the Bavari laboratory at USAMRID), which is the only strain used in this study. Junin virus production was performed by inoculation of JUNV (passage 2) to sub-confluent Vero cells at a multiplicity of infection of 0.5 in a low volume of Virus media: DMEM (Life Technologies-Gibco) supplemented with 2% heat inactivated FBS (Atlanta Biologicals), 100 IU mL<sup>-1</sup> penicillin and 100 mg mL<sup>-1</sup> streptomycin and 2 mM L-Glutamine (Life Technologies-Gibco). After 1 hr, additional media was provided and cells were incubated for 72 hrs at 37°C, 5% CO<sub>2</sub>. Supernatant was harvested and cleared from cellular debris by centrifugation at 10,000 g at 4°C for 10 min. The virus-containing supernatant was then frozen at -80°C before use. Viruses were titrated by plaque assay on Vero cells.

### Virus labeling

JUNV stock was incubated with a non-neutralizing mouse monoclonal antibody raised against the JUNV Envelope glycoprotein (4 µg mL<sup>-1</sup>; LD05-BF09; NR-2569; BEI resources), coupled to an Alexa Fluor 647 (4 µg mL<sup>-1</sup>; Life Technologies) for 30 min at 25°C. Viruses were also labeled with YOYO-1 (100 nM; Life Technologies), CD9 monoclonal antibody conjugated to Phycoerythrin (PE; 1 µg mL<sup>-1</sup>; BD Biosciences) or Cholera Toxin Subunit B conjugated to Fluorescein isothiocyanate (FITC; 4 µg mL<sup>-1</sup>; Sigma-Aldrich) according to the experiment. The virus-dye mixture was then gently applied on top of a 10% Optiprep (Sigma-Aldrich) cushion and ultracentrifuged at 150,000g for 2 hrs at 4°C using rotor SW55 Ti (Beckman Coulter). Supernatant was discarded and pellets were resuspended in 0.2 µm filtered PBS, 1% BSA and left overnight in the dark at 4°C for gentle solubilization. The preparation was used the next day for Flow virometry assays.

### Monocyte-derived macrophages

Blood of healthy donors was obtained from the Kraft Family Blood Donor Center (informed consent signed by the donors). Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll (GE Healthcare). Monocytes were purified by positive selection using CD14+ Microbeads (Miltenyi) and differentiated into macrophages for 7 days in RPMI (Life Technologies-Gibco) supplemented with 10% fetal bovine serum, heat inactivated at 56°C, Premium select triple 0.1 µm filtered (FBS; Atlanta Biologicals), 100 IU mL<sup>-1</sup> penicillin and 100 mg mL<sup>-1</sup> streptomycin, 2 mM L-Glutamine (Life Technologies-Gibco) and supplemented with 25 ng mL<sup>-1</sup> macrophage colony-stimulating factor (M-CSF) as in <sup>39</sup>.

### RNA analysis

Total RNA from cells was purified using the RNeasy Mini kit (Qiagen). Reverse transcription and real time quantitative PCR (RT-qPCR) amplifications were performed

using the one step QuantiFast SYBR Green RT-PCR kit (Qiagen). Viral and cellular DNAs were detected using specific primers for the Short segment (5'-cctagcgcttcaggaagatcc-3' and 5'-caccagctcatatctgctggatg-3'), the Large segment (5'-ggagggtagctcacagcagtc-3' and 5'-ctatggtggtgctgttggc-3') and the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 5'-gagtcaacggattggtcgt-3' and 5'-tgatttggaggatctcg-3'). The amplification conditions were as follow: Reverse transcription, 10 min at 50°C; PCR initial activation step, 5 min at 95°C; 40 cycles of denaturation and combined annealing/extension, 10 sec at 95°C and 30 sec at 60°C, respectively. Fluorescence data collection was acquired at the end of each cycle, and a melting curve showing specificity of the primers used was included at the end of each PCR reaction.

### Flow virometry assay (FVA) and sorting

A 15-channel FACS Aria II Special Order (SORP) cell sorter cytometer (BD Biosciences) equipped with a combination of 355 nm, 407 nm, 488 nm, 640 nm, 594 nm lasers was used. Fluorescence emission was collected through 530/30 (FITC), 575/25 (PE) and 660/20 (Alexa 647) bandpass filters. The instrument was upgraded with a high-powered 488 nm, 300 mW (263 mW at the stream) special order laser (Coherent Inc), a variable digital focusing system (DFS) option and laser tunable software, Coherent Connection (Coherent Inc). The forward scatter includes a high-sensitivity photomultiplier tube (FSC-PMT) and improved collection optics, allowing the detection of nanosized microvesicles and viral particles<sup>5,6</sup>. Fluid sheath running through the cytometer was highly filtered (0.45 µM and 0.1 µM filters). Sorting was performed with a 70 µm nozzle, a pressure of 70 psi (482 kPa) and frequency of 87,500. The droplet size was experimentally measured to be 1.5 to 1.7 nl. Preliminary set up and alignment of the FSC-PMT-A was performed using a set of polystyrene size beads (300, 500, 800 nm; BD Biosciences) and fluorochrome-conjugated carboxylated-modified latex beads (40 nm APC-conjugated and 100 nm PE-conjugated beads; Life Technologies). The DFS consists of a tunable picomotor-driven device that allows accurate adjustment of the laser beam size at the core of the stream, therefore increasing the scatter signal and decreasing the background. Prior to start experiments, the DFS optimal parameters were determined on dedicated BD software using Megamix Plus-FSC beads (BioCytex). All data was analyzed using FACSDiva 6.1 (BD Biosciences) and FlowJo 10.0.7 (Treestar Inc) software.

### Tunable Resistive Pulse Sensing

JUNV-A647 preparation resuspended in filtered PBS was sorted or not and then applied on a qViro system (IZON Science) as described in ref.<sup>18</sup>. Briefly, 40 µl of the viral preparation in ultra-filtered PBS was added on top of a thermoplastic polyurethane membrane with a single nano-pore (NP150) at 46.87 mm stretch, 0.70 V and 1.2 KPa of applied pressure. The ionic current and resistive pulse signals were collected using IZON proprietary software. The measurement was calibrated using 115 nm polystyrene calibration beads (Bangs Laboratories) with a concentration.

### Virus infectivity assays

Infectivity of JUNV was measured by plaque assay or by flow cytometry. For plaque assay, confluent Vero cells were inoculated with serial dilution of JUNV for 1 hr at 37°C. Cells

were then covered with an overlay composed of 1% agarose diluted in Virus media. Five days post-infection, cells were fixed with 10% Formaldehyde for 30 min. The overlay was then discarded and the cell monolayer was stained with 0.05% Crystal Violet in 10% Ethanol. Plaques were counted in the well containing the appropriate virus dilution. For flow cytometry, Vero cells were infected with particles sorted by FVA. After 16 hrs, cells were harvested, fixed with 4% paraformaldehyde and permeabilized with 0.5% bovine serum albumin (BSA) and 0.05% Saponin in PBS, followed by incubation with a mouse monoclonal antibody ( $2 \mu\text{g ml}^{-1}$ ; SA02-BG12; NR-2573; BEI resources) specific for the JUNV nucleoprotein (NP) and coupled to an Alexa Fluor 647. Acquisition of fluorescence intensity of the infected cells was performed on a FACSCanto II with 488 and 640 nm lasers (BD Biosciences). Analysis of the percentage of infected cells was completed using FlowJo version 10.0.7 (Treestar Inc).

### **Immunofluorescence and light microscopy**

Infected Vero cells were fixed, permeabilized with 0.5% bovine serum albumin (BSA) and 0.05% Saponin in PBS and co-stained with a mouse monoclonal antibody ( $4 \mu\text{g ml}^{-1}$ ; GD01-AG02; NR-2565; BEI resources) specific for the JUNV Glycoprotein (GPC) and conjugated to an Alexa Fluor 488 and the CD9 monoclonal antibody conjugated to PE ( $2 \mu\text{g ml}^{-1}$ ; BD Biosciences). The samples were imaged on a Zeiss AxioObserver.Z1 inverted microscope mounted with a spinning disc head (Yokogawa), a QuantEM:512SC EMCCD camera (Photometrics) and a 100 $\times$ , 1.4 NA oil objective (Zeiss).

### **Transmission Electron Microscopy**

Low and high fractions were sorted directly on glow-discharged carbon-coated TEM grids (Electron Microscopy Sciences). Samples were then incubated with the uncoupled mouse monoclonal antibody raised against GPC ( $10 \mu\text{g ml}^{-1}$ ; GD01-AG02; NR-2565; BEI resources), followed by a secondary Rabbit anti-mouse antibody (MP Biomedicals) and revealed by Protein A conjugated to 10 nm gold beads. Negative staining was achieved by incubating samples in Uranyl formate (Electron Microscopy Sciences) for 30 sec. The grids were examined on a JEOL 1200EX Transmission electron microscope and images were recorded with an AMT 2k CCD.

### **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

### **Acknowledgments**

We are thankful to Larry Duckett, David Matsuyama and Paul Melanson, BD Biosciences, Inc (San Jose, CA) for their help with the cytometer's upgrade and functionality. We are grateful to Dr. Michael W. Olszowy (Life Technologies) for providing the 40 and 100 nm fluorescent beads. We thank Lloyd Bahlmann for giving us access to Izon technology. We also thank Tom Kirchhausen for letting us use his laboratory and microscopes and Ivan Vorobjev for his helpful advice. We thank Frances Evesson for her comments and critical reading of the manuscript. We greatly acknowledge the Harvard Medical School Electron Microscopy facility. NSB was supported by the Harvard Pilot Grant and PCMM/Boston Children's Hospital. RG was supported by the National Institutes of Health Grants GM-075252 and U54 AI057159 (New England Regional Center of Excellence in Biodefense and Emerging Infectious Diseases [NERCE BEID]).

## References

1. Marie D, Brussaard CPD, Thyraug R, Bratbak G, Vaultot D. Enumeration of marine viruses in culture and natural samples by flow cytometry. *Applied and environmental microbiology*. 1999; 65:45–52. [PubMed: 9872758]
2. Nolte-t Hoen EN, et al. Quantitative and qualitative flow cytometric analysis of nanosized cell-derived membrane vesicles. *Nanomedicine: nanotechnology, biology, and medicine*. 2012; 8:712–720.10.1016/j.nano.2011.09.006
3. van der Vlist EJ, Nolte-t Hoen EN, Stoorvogel W, Arksteijn GJ, Wauben MH. Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry. *Nature protocols*. 2012; 7:1311–1326.10.1038/nprot.2012.065 [PubMed: 22722367]
4. Nolte-t Hoen EN, et al. Dynamics of dendritic cell-derived vesicles: high-resolution flow cytometric analysis of extracellular vesicle quantity and quality. *Journal of leukocyte biology*. 2013; 93:395–402.10.1189/jlb.0911480 [PubMed: 23248328]
5. Steen HB. Flow cytometer for measurement of the light scattering of viral and other submicroscopic particles. *Cytometry. Part A: the journal of the International Society for Analytical Cytology*. 2004; 57:94–99.10.1002/cyto.a.10115 [PubMed: 14750130]
6. Hercher M, Mueller W, Shapiro HM. Detection and discrimination of individual viruses by flow cytometry. *The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society*. 1979; 27:350–352. [PubMed: 374599]
7. Arakelyan A, Fitzgerald W, Margolis L, Grivel JC. Nanoparticle-based flow virometry for the analysis of individual virions. *The Journal of clinical investigation*. 2013; 123:3716–3727.10.1172/JCI67042 [PubMed: 23925291]
8. Allen LZ, et al. Single virus genomics: a new tool for virus discovery. *PloS one*. 2011; 6:e17722.10.1371/journal.pone.0017722 [PubMed: 21436882]
9. Maiztegui JI, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. *The Journal of infectious diseases*. 1998; 177:277–283. [PubMed: 9466512]
10. Radoshitzky SR, et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. *Nature*. 2007; 446:92–96.10.1038/nature05539 [PubMed: 17287727]
11. Flanagan ML, et al. New world clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. *Journal of virology*. 2008; 82:938–948.10.1128/JVI.01397-07 [PubMed: 18003730]
12. Cuevas CD, Lavanya M, Wang E, Ross SR. Junin virus infects mouse cells and induces innate immune responses. *Journal of virology*. 2011; 85:11058–11068.10.1128/JVI.05304-11 [PubMed: 21880772]
13. Lavanya M, Cuevas CD, Thomas M, Cherry S, Ross SR. siRNA screen for genes that affect Junin virus entry uncovers voltage-gated calcium channels as a therapeutic target. *Science translational medicine*. 2013; 5:204ra131.10.1126/scitranslmed.3006827
14. Nolan JP, Stoner SA. A trigger channel threshold artifact in nanoparticle analysis. *Cytometry. Part A: the journal of the International Society for Analytical Cytology*. 2013; 83:301–305.10.1002/cyto.a.22255 [PubMed: 23335161]
15. Neuman BW, et al. Complementarity in the supramolecular design of arenaviruses and retroviruses revealed by electron cryomicroscopy and image analysis. *Journal of virology*. 2005; 79:3822–3830.10.1128/JVI.79.6.3822-3830.2005 [PubMed: 15731275]
16. Sanchez A, et al. Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. *The Journal of general virology*. 1989; 70(Pt 5):1125–1132. [PubMed: 2471803]
17. van der Pol E, Coumans F, Varga Z, Krummy M, Nieuwland R. Innovation in detection of microparticles and exosomes. *Journal of thrombosis and haemostasis: JTH*. 2013; 11(Suppl 1):36–45.10.1111/jth.12254 [PubMed: 23809109]

18. Vogel R, et al. Quantitative sizing of nano/microparticles with a tunable elastomeric pore sensor. *Analytical chemistry*. 2011; 83:3499–3506.10.1021/ac200195n [PubMed: 21434639]
19. Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. *The Journal of cell biology*. 1998; 141:929–942. [PubMed: 9585412]
20. Silvie O, et al. Cholesterol contributes to the organization of tetraspanin-enriched microdomains and to CD81-dependent infection by malaria sporozoites. *Journal of cell science*. 2006; 119:1992–2002.10.1242/jcs.02911 [PubMed: 16687736]
21. Danthi P, Chow M. Cholesterol removal by methyl-beta-cyclodextrin inhibits poliovirus entry. *Journal of virology*. 2004; 78:33–41. [PubMed: 14671085]
22. Hoffman, RA. Pulse width for particle sizing. In: Paul Robinson, J., et al., editors. *Current protocols in cytometry*. Vol. Chapter 1. 2009.
23. Ramdzan YM, et al. Tracking protein aggregation and mislocalization in cells with flow cytometry. *Nature methods*. 2012; 9:467–470.10.1038/nmeth.1930 [PubMed: 22426490]
24. Cureton DK, Harbison CE, Cocucci E, Parrish CR, Kirchhausen T. Limited transferrin receptor clustering allows rapid diffusion of canine parvovirus into clathrin endocytic structures. *Journal of virology*. 2012; 86:5330–5340.10.1128/JVI.07194-11 [PubMed: 22357278]
25. Pang Y, Song H, Kim JH, Hou X, Cheng W. Optical trapping of individual human immunodeficiency viruses in culture fluid reveals heterogeneity with single-molecule resolution. *Nature nanotechnology*. 2014; 9:624–630.10.1038/nnano.2014.140
26. Kuhn RJ, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. *Cell*. 2002; 108:717–725. [PubMed: 11893341]
27. Zhu P, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. *Nature*. 2006; 441:847–852.10.1038/nature04817 [PubMed: 16728975]
28. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. *Journal of virology*. 2005; 79:12132–12147.10.1128/JVI.79.19.12132-12147.2005 [PubMed: 16160141]
29. Campetella OE, Sanchez A, Giovanniello OA. In vivo Junin virus-mouse macrophages interaction. *Acta virologica*. 1988; 32:198–206. [PubMed: 2902768]
30. Groseth A, et al. Tacaribe virus but not junin virus infection induces cytokine release from primary human monocytes and macrophages. *PLoS neglected tropical diseases*. 2011; 5:e1137.10.1371/journal.pntd.0001137 [PubMed: 21572983]
31. Cordo SM, Valko A, Martinez GM, Candurra NA. Membrane localization of Junin virus glycoproteins requires cholesterol and cholesterol rich membranes. *Biochemical and biophysical research communications*. 2013; 430:912–917.10.1016/j.bbrc.2012.12.053 [PubMed: 23261443]
32. Agnihothram SS, et al. Assembly of arenavirus envelope glycoprotein GPC in detergent-soluble membrane microdomains. *Journal of virology*. 2009; 83:9890–9900.10.1128/JVI.00837-09 [PubMed: 19625404]
33. Hogue IB, Grover JR, Soheilian F, Nagashima K, Ono A. Gag induces the coalescence of clustered lipid rafts and tetraspanin-enriched microdomains at HIV-1 assembly sites on the plasma membrane. *Journal of virology*. 2011; 85:9749–9766.10.1128/JVI.00743-11 [PubMed: 21813604]
34. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. *Blood*. 1999; 94:3791–3799. [PubMed: 10572093]
35. Haqqani AS, et al. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. *Fluids and barriers of the CNS*. 2013; 10:4.10.1186/2045-8118-10-4 [PubMed: 23305214]
36. Kenworthy AK, Petranova N, Edidin M. High-resolution FRET microscopy of cholera toxin B-subunit and GPI-anchored proteins in cell plasma membranes. *Molecular biology of the cell*. 2000; 11:1645–1655. [PubMed: 10793141]
37. Tuosto L, et al. Organization of plasma membrane functional rafts upon T cell activation. *European journal of immunology*. 2001; 31:345–349.10.1002/1521-4141(200102)31:2<345::AID-IMMU345>3.0.CO;2-L [PubMed: 11180097]


38. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. *Science*. 1999; 283:680–682. [PubMed: 9924026]
39. Gaudin R, et al. Critical role for the kinesin KIF3A in the HIV life cycle in primary human macrophages. *The Journal of cell biology*. 2012; 199:467–479.10.1083/jcb.201201144 [PubMed: 23091068]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 1.**

Flow cytometry analysis of small particles. (a–d) 40 nm APC-conjugated latex beads (a,b) and 100 nm PE-conjugated latex beads (c,d) were analyzed on our custom-made flow cytometer and plotted for APC fluorescence (a,c) or PE fluorescence (b,d) as a function of the FSC-PMT parameter. The 40 nm and 100 nm beads were specifically detected from their respective fluorophores. (e) Junin viruses concentrated by ultracentrifugation were adsorbed on carbon-coated TEM grids and labeled with the GPC specific LD05 mouse monoclonal antibody followed by a secondary anti-mouse antibody and revealed by Protein A 10 nm gold beads. Contrast was obtained by negative staining. Bar = 50 nm. JUNV particles of various sizes were all positive for the GPC antibody staining. (f,g) Flow virometry analysis of PBS (f) or purified viral particles stained with a GPC antibody coupled to an Alexa Fluor 647 (JUNV-A647; g). The plot shows Alexa 647 GPC fluorescence versus FSC-PMT. Both samples were run using the same parameters, at the same speed and for the same amount of




time. **(g)** Several populations could be distinguished and are pointed out by labeled arrows. Fluorescence-based thresholding was used to decrease noise events. **(h)** Non-fluorescent polystyrene beads of larger size (300, 500 and 800 nm) were detected by FSC-PMT channel only. The area between the two first gray dashed lines shows FSC-PMT events that are at the level of the background. The area between the second and third dashed lines correspond to events above background but smaller than 300 nm.

Author Manuscript


Author Manuscript

Author Manuscript


Author Manuscript




**Figure 2.** Sorting of infectious viruses by flow virometry. **(a,b)** JUNV-A647 particles were sorted directly onto carbon-coated TEM grids and labeled with the GPC specific GD01 antibody followed by a secondary antibody, then revealed by Protein A 10 nm gold beads. The low **(a)** and high **(b)** fractions were negatively staining and analyzed by transmission electron microscopy. Several particles per micrograph are shown and the images are representative of each population. The low fraction viruses are about 60 nm in diameter, while the high fraction viruses are around 150 nm. **(c)** Tunable Resistive Pulse Sensing (TRPS) was performed on unsorted (blue bars) or sorted particles smaller than 300 nm (pink bars). The histograms show the distribution of particle size detected in each sample.

**Figure 3.**

Infectious properties of sorted particles from the low and high fractions. **(a,b)** Confluent Vero cells were infected with 3,000 sorted particles in 300  $\mu$ l virus media for 1h, subsequently overlaid with Virus media containing 1% melted agarose and incubated for 5 days. Plaques forming units were revealed by crystal violet staining. **(a)** Images correspond to plaques observed in representative wells infected with 3,000 particles from the low (left) and high (right) fractions. **(b)** Quantification of the percentage of infectious particles from the low and high fractions. Error bars are mean  $\pm$  s.d. of duplicates and the histogram is representative of four independent experiments. **(c)** Relative amount of RNA contained in 20,000 sorted particles for each fraction. Reverse transcriptase RT-qPCR with primers targeting the Short (blue) or the Large (red) segment of JUNV is shown. Low and high fractions showed similar RNA levels for both Short and Large segments. Error bars are the mean  $\pm$  s.d. of triplicates and the data is representative of 2 independent experiments. **(d)** Ratio of the relative amount of Short to Large segment in the low and high fractions and in the virus stock. RNA ratio remains constant in all three samples. **(e)** Quantification of the percentage of infectious particles produced by Vero cells (black bars) or human primary macrophages (green bars) from the low and high fractions. **(f)** Relative amount of RNA contained in 15,000 sorted particles from Vero cells (black bars) or human primary macrophages (green bars). Reverse transcriptase RT-qPCR with primers targeting the Short or the Large segment of JUNV is shown. Error bars are the mean  $\pm$  s.d. of triplicates.

**Figure 4.**

Correlation between Glycoprotein (GPC) levels and RNA content. Flow virometry assay of JUNV particles stained with Alexa 647 GPC antibody only (a) or YOYO-1 only (b). Dot plots represent nucleic acid dye fluorescence (x axis) as a function of the Alexa 647 GPC fluorescence (y axis). (c) Flow virometry analysis of particles stained with both Alexa 647 GPC antibody and the nucleic acid dye YOYO-1. (d) Pie charts representing the percentage of potentially infectious particles (GPC<sup>+</sup> RNA<sup>+</sup>) in the low and high fractions. The high fraction contains about 2.5 times more virions with both genetic material and surface GPC than the low fraction. (e, f) Relative amount of RNA contained in 20,000 sorted particles from total RNA<sup>+</sup> or GPC<sup>+</sup> RNA<sup>+</sup> viral particles. Reverse transcriptase RT-qPCR with primers targeting the Short (e) or the Large (f) segment of JUNV is shown. Error bars are the mean  $\pm$  s.d. of triplicates.



**Figure 5.**

Junin virus buds at CD9-enriched sites. JUNV-A647 viral particles stained with either a CD9 antibody conjugated to PE (a) or Cholera Toxin B (CTB) conjugated to FITC (b) were analyzed by flow virometry and plotted as a function of Alexa 647 GPC antibody staining. (c) JUNV particles stained with a GPC antibody coupled to an Alexa Fluor 647 as in Figure 1g, were adsorbed on glow discharged glass coverslip. Samples were blocked in 0.5% BSA in PBS for 30 min, incubated with mouse anti-CD9 antibody coupled to PE for 30 min and then washed extensively in 0.5% BSA in PBS. Coverslips were mounted on slides and image by spinning disk confocal microscopy. The micrograph represents CD9-PE (red) and JUNV-A647 (cyan) and the red channel was shifted by 6 pixels up in order to better appreciate colocalization of the two fluorophores. Over 500 JUNV-A647 particles were counted and Pearson correlation with CD9-PE was evaluated at  $0.77 \pm 0.1$ . Bar = 5  $\mu\text{m}$ . (d) Vero cells infected with JUNV for 24 hrs were fixed, permeabilized and stained with a CD9 antibody conjugated to PE and the GPC specific GD01 antibody conjugated to Alexa Fluor 488. Images were acquired by spinning disk confocal microscopy and represent the plasma membrane of an infected cell. The images show CD9 staining (upper panel), GPC staining (middle panel) and the overlay of the two channels (bottom panel). The pink arrows


highlight GPC positive spots, likely corresponding to budding events that are enriched in CD9. Bar = 5  $\mu$ m.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 6.**

Cholesterol depletion of producer cells decreases infectivity of budding viruses. Vero cells infected for 24 hrs with JUNV were mock-treated (**a**) or treated with 10 mM Methyl- $\beta$ -Cyclodextrin (M $\beta$ CD-treated; **b**) for 1 hr at 37°C. Cells were then extensively washed with PBS and incubated for an additional 12 hrs at 37°C. Subsequently, supernatant was harvested and stained with LD05 GPC antibody conjugated to Alexa Fluor 647 and CD9 antibody conjugated to PE as in Figure 5a. Dot plots show CD9 antibody fluorescence as a function of Alexa 647 GPC antibody staining. Percentages in each corner indicate the proportion of each population in the given quadrant. The data shows that M $\beta$ CD treatment strongly decreases CD9 at the surface of virions. (**c**) JUNV-A647 particles from M $\beta$ CD or mock treated producer cells were sorted and 8,000 particles per conditions were used to infect Vero cells for 16 hrs. Subsequently, Vero cells were stained with a viral Nucleoprotein specific antibody conjugated to an Alexa Fluor 647 and analyzed by flow cytometry to measure the percentage of infected cells. A two-fold decrease in infectivity was observed when producer cells were treated with M $\beta$ CD compared to the mock condition. Error bars are the mean  $\pm$  s.d. of duplicates where at least 10,000 cells per sample were acquired. The difference marked by the star is significant (unpaired t-test p value = 0.024).